EUS RFA for Treatment of Pancreatic Ductal Adenocarcinoma (PDAC)

PHASE1RecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

March 31, 2023

Primary Completion Date

November 30, 2026

Study Completion Date

March 31, 2027

Conditions
Pancreatic Cancer
Interventions
DRUG

Chemotherapy

Patients will receive continuation of second or initiate third-line chemotherapy regimen at the discretion and decision of treating oncologist.

DEVICE

Endoscopic Ultrasound-Guided Radiofrequency Ablation (EUS-RFA)

"EUS-RFA will be delivered using the EUSRA RF Electrode, which is a sterile, single-use electrosurgical accessory for coagulation and ablation of soft tissue when used in conjunction with compatible radio frequency generator (VIVA Combo RF Generator).~The device will be used during a routine EUS, which is a minimally invasive procedure used to assess gastrointestinal diseases. Each EUS-RFA procedure will last approximately 60 minutes."

Trial Locations (1)

10016

RECRUITING

Tisch Hospital, New York

All Listed Sponsors
collaborator

Taewoong Medical

UNKNOWN

lead

NYU Langone Health

OTHER